| scholarly article | Q13442814 |
| P2093 | author name string | Glauber HS | |
| Wallace P | |||
| Henry RR | |||
| Lyon R | |||
| Ditzler T | |||
| Gumbiner B | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | insulin therapy | Q2002370 |
| type 2 diabetes | Q3025883 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 21-31 | |
| P577 | publication date | 1993-01-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial | |
| P478 | volume | 16 |
| Q92074411 | A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes |
| Q28219083 | A low-carbohydrate diet may prevent end-stage renal failure in type 2 diabetes. A case report |
| Q47898086 | A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. |
| Q33426771 | Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. |
| Q38266858 | Are you ready for more insulin concentrations? |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q33703334 | Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus |
| Q37632407 | Challenges and advances in nanoparticle-based oral insulin delivery. |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q36117595 | Diabetes mellitus: new challenges and innovative therapies |
| Q73232157 | Diet and exercise in type 2 diabetes mellitus |
| Q71175243 | Discrepancies between perceived dietary changes and 4-day food records in older adults with diabetes |
| Q46872134 | Does a patient-administered titration algorithm of insulin glargine improve glycemic control? |
| Q43919658 | Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study |
| Q51289192 | Effect of low-glycemic-sugar-sweetened beverages on glucose metabolism and macronutrient oxidation in healthy men. |
| Q44848283 | Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients |
| Q50125577 | Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study |
| Q51589248 | Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients |
| Q43641813 | Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. |
| Q51589992 | Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents |
| Q41746158 | Focus on insulin resistance in type 2 diabetes: therapeutic implications |
| Q33595021 | Glucose control guidelines: current concepts |
| Q33828255 | Glucose supply and insulin demand dynamics of antidiabetic agents |
| Q40390203 | Glycaemia control in diabetes mellitus. Towards the normal profile? |
| Q71076828 | Glycemic control in diabetes mellitus: have changes in therapy made a difference? |
| Q34722593 | Hepatic glucose production: therapeutic target in type 2 diabetes? |
| Q35690608 | Hypoglycemia as a barrier to glycemic control |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q46810804 | Importance of glucose control |
| Q42435709 | Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion |
| Q50957789 | Insulin Resistance, Obesity and Lipotoxicity. |
| Q54083197 | Insulin dose-response studies in severely insulin-resistant type 2 diabetes--evidence for effectiveness of very high insulin doses. |
| Q33880303 | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 |
| Q44597485 | Insulin therapy improves insulin actions on glucose metabolism and aortic wave reflection in type 2 diabetic patients |
| Q34451782 | Insulin therapy in type 2 diabetes |
| Q73531395 | Insulin therapy in type 2 diabetes |
| Q36383552 | Insulin treatment increases myocardial ceramide accumulation and disrupts cardiometabolic function |
| Q36966075 | Insulin-associated weight gain in diabetes--causes, effects and coping strategies |
| Q39309680 | Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? |
| Q47603482 | Insulin-loaded PLGA microspheres for glucose-responsive release |
| Q43864993 | Insulin-metformin combination therapy in obese patients with type 2 diabetes |
| Q36783839 | Insulin: potential negative consequences of early routine use in patients with type 2 diabetes |
| Q27860882 | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group |
| Q36946307 | Intensive diabetes therapy and body weight: focus on insulin detemir |
| Q92970677 | Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial |
| Q72662551 | Management of non-insulin-dependent diabetes mellitus |
| Q36679153 | New concepts in diabetes mellitus. I: Treatment, pregnancy and aetiology |
| Q41716386 | Non-insulin dependent diabetes in children and adolescents: the therapeutic challenge |
| Q34187544 | Non-insulin dependent diabetes mellitus in Mexican-American children. |
| Q41455243 | Non-insulin-dependent diabetes mellitus in childhood and adolescence |
| Q27026847 | Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia |
| Q33792579 | Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals |
| Q40977732 | Preventing complications in diabetes mellitus: the role of the primary care physician |
| Q43554627 | Role and modalities of insulin treatment in type 2 diabetics |
| Q28254202 | Serum glucose control in diabetic patients with cardiovascular disease: should we be less aggressive? |
| Q41603358 | Tactics for type II diabetes |
| Q40049756 | The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes |
| Q44500010 | The changing model of insulin use in type 2 diabetes. Techniques, tactics for getting to goal |
| Q43923302 | The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. |
| Q34292419 | The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus |
| Q35563453 | The management of the obese diabetic patient |
| Q33487688 | The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus |
| Q34906374 | The underuse of insulin therapy in North America |
| Q35907234 | The use of bolus insulin and advancing insulin therapy in type 2 diabetes |
| Q33752794 | The use of insulin alone and in combination with oral agents in type 2 diabetes |
| Q43979001 | Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention |
| Q45249089 | Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the 'Darwin study'. |
| Q58795412 | Use of dapagliflozin in patients with advanced diabetic kidney disease |
| Q37767088 | Using insulin pump therapy in poorly controlled type 2 diabetes |
| Q34580999 | Where thiazolidinediones will fit. |
| Q33354192 | Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? |
Search more.